Australia markets open in 9 hours 51 minutes

Tasly Pharmaceutical Group Co., Ltd (600535.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
15.91-0.03 (-0.19%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 23.81B
Enterprise value 21.66B
Trailing P/E 21.54
Forward P/E 17.21
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.75
Price/book (mrq)1.88
Enterprise value/revenue 2.51
Enterprise value/EBITDA 16.78

Trading information

Stock price history

Beta (5Y monthly) 0.39
52-week change 37.05%
S&P500 52-week change 325.77%
52-week high 318.00
52-week low 312.88
50-day moving average 316.12
200-day moving average 315.20

Share statistics

Avg vol (3-month) 314.71M
Avg vol (10-day) 315.71M
Shares outstanding 51.49B
Implied shares outstanding 61.49B
Float 8767.88M
% held by insiders 150.69%
% held by institutions 16.99%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.33
Forward annual dividend yield 42.07%
Trailing annual dividend rate 30.33
Trailing annual dividend yield 32.07%
5-year average dividend yield 42.30
Payout ratio 444.59%
Dividend date 3N/A
Ex-dividend date 422 May 2023
Last split factor 21.4:1
Last split date 305 June 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 12.75%
Operating margin (ttm)19.26%

Management effectiveness

Return on assets (ttm)4.99%
Return on equity (ttm)8.13%

Income statement

Revenue (ttm)8.64B
Revenue per share (ttm)5.78
Quarterly revenue growth (yoy)-1.70%
Gross profit (ttm)N/A
EBITDA 1.82B
Net income avi to common (ttm)1.1B
Diluted EPS (ttm)0.74
Quarterly earnings growth (yoy)11.60%

Balance sheet

Total cash (mrq)4.86B
Total cash per share (mrq)3.25
Total debt (mrq)2.71B
Total debt/equity (mrq)20.86%
Current ratio (mrq)3.36
Book value per share (mrq)8.47

Cash flow statement

Operating cash flow (ttm)2.09B
Levered free cash flow (ttm)1.63B